Modality
Gene Editing
MOA
KIF18Ai
Target
LAG-3
Pathway
Fibrosis
Alzheimer's
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
~Mar 2018
→ ~Jun 2019
NDA/BLA
~Sep 2019
→ ~Dec 2020
Approved
Mar 2021
→ Apr 2030
ApprovedCurrent
NCT08856148
107 pts·Alzheimer's
2021-03→2030-04·Completed
107 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-04-204.1y awayPh3 Readout· Alzheimer's
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Complet…
Catalysts
Ph3 Readout
2030-04-20 · 4.1y away
Alzheimer's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08856148 | Approved | Alzheimer's | Completed | 107 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |